KLRB1 and glioblastoma: Finally, the PFI analysis showed that CD161 acts as a protective factor for patients with ACC, CESC, CHOL, HNSC, LIHC, LUAD, MESO, SKCM, and UCEC and a risk factor for patients with GBM (Figure 5D).